These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 24048238)
1. Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation? Gouda P; Ezekowitz JA Clin Pharmacol Ther; 2013 Oct; 94(4):435-8. PubMed ID: 24048238 [TBL] [Abstract][Full Text] [Related]
2. Antithrombotic therapy for heart failure in sinus rhythm. Subramaniam V; Davis RC; Shantsila E; Lip GY Fundam Clin Pharmacol; 2009 Dec; 23(6):705-17. PubMed ID: 19735305 [TBL] [Abstract][Full Text] [Related]
3. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Gorin L; Fauchier L; Nonin E; de Labriolle A; Haguenoer K; Cosnay P; Babuty D; Charbonnier B Thromb Haemost; 2010 Apr; 103(4):833-40. PubMed ID: 20135077 [TBL] [Abstract][Full Text] [Related]
4. Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. Kim JH; Shah P; Tantry US; Gurbel PA Curr Heart Fail Rep; 2016 Dec; 13(6):319-328. PubMed ID: 27815681 [TBL] [Abstract][Full Text] [Related]
5. Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. Gurbel PA; Tantry US JACC Heart Fail; 2014 Feb; 2(1):1-14. PubMed ID: 24622113 [TBL] [Abstract][Full Text] [Related]
6. Quality of care for atrial fibrillation among patients hospitalized for heart failure. Piccini JP; Hernandez AF; Zhao X; Patel MR; Lewis WR; Peterson ED; Fonarow GC; J Am Coll Cardiol; 2009 Sep; 54(14):1280-9. PubMed ID: 19778670 [TBL] [Abstract][Full Text] [Related]
7. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Lip GY Thromb Haemost; 2010 Apr; 103(4):683-5. PubMed ID: 20135056 [No Abstract] [Full Text] [Related]
8. [Atrial fibrillation and thromboembolic events prevention. State of the art]. Matteoli S; Trappolini M; Chillotti FM Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381 [TBL] [Abstract][Full Text] [Related]
9. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. Hohnloser SH; Pajitnev D; Pogue J; Healey JS; Pfeffer MA; Yusuf S; Connolly SJ; J Am Coll Cardiol; 2007 Nov; 50(22):2156-61. PubMed ID: 18036454 [TBL] [Abstract][Full Text] [Related]
10. Antiplatelet drugs in cardiovascular prevention: stroke prevention in patients with thrombogenic heart disease. Prescrire Int; 2000 Jun; 9(47):87-8. PubMed ID: 11010751 [TBL] [Abstract][Full Text] [Related]
11. Review: anticoagulants may be better than antiplatelet agents for nonfatal stroke but not other vascular or fatal events in nonrheumatic AF. Ebrahim S; Taylor F ACP J Club; 2001; 135(2):A17. PubMed ID: 11571899 [No Abstract] [Full Text] [Related]
12. Stroke prevention in elderly patients with atrial fibrillation. Lew SJ; Lim JK Singapore Med J; 2002 Apr; 43(4):198-201. PubMed ID: 12188065 [TBL] [Abstract][Full Text] [Related]
13. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Ahmad Y; Lip GY; Apostolakis S Expert Rev Cardiovasc Ther; 2012 Dec; 10(12):1471-80. PubMed ID: 23253272 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study. Tsivgoulis G; Spengos K; Zakopoulos N; Manios E; Peppes V; Vemmos K Age Ageing; 2005 Jan; 34(1):35-40. PubMed ID: 15591481 [TBL] [Abstract][Full Text] [Related]
16. Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. Eikelboom JW; Hart RG Am J Hematol; 2012 May; 87 Suppl 1():S100-7. PubMed ID: 22389052 [TBL] [Abstract][Full Text] [Related]
17. [Should we add antiplatelet therapy to oral anticoagulation in patients with atrial fibrillation and vascular disease? Review of available evidence]. Andreu JM; Roldán V; García-Navarro M; Ruipérez JA; Valdés M; Marín F Arch Cardiol Mex; 2012; 82(3):248-51. PubMed ID: 23021363 [TBL] [Abstract][Full Text] [Related]
18. [Antithrombotic prophylaxis in patients with ventricular dysfunction: critical review of the literature and new perspectives]. Scardi S; Mazzone C Ital Heart J Suppl; 2003 Mar; 4(3):201-9. PubMed ID: 12784754 [TBL] [Abstract][Full Text] [Related]
19. Oral anticoagulation in patients with cardiomyopathy or heart failure in sinus rhythm. Pullicino P; Thompson JL; Mohr JP; Sacco RL; Freudenberger R; Levin B; Homma S Cerebrovasc Dis; 2008; 26(3):322-7. PubMed ID: 18667814 [TBL] [Abstract][Full Text] [Related]